Epstein-Barr Viral Gene Expression in B-Lymphocytes

References

• Henle G., Henle W., Diehl V. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci V S A 1968; 59: 94–101
   PubMed Web of Science ®Google Scholar
• Sixbey J. W., Nedrud J. G., Raab Traub N., Hanes R. A., Pagano J. S. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 1984; 310: 1225–1230
   PubMed Web of Science ®Google Scholar
• Sixbey J. W., Vesterinen E. H., Nedrud J. G., Raab Traub N., Walton L. A., Pagano J. S. Replication of Epstein-Barr virus in human epithelial cells infected in vitro. Nature 1983; 306: 480–483
   PubMed Web of Science ®Google Scholar
• Becker J., Leser U., Marschall M., Langford A., Jilg W., Gelderblom H., Reichart P., Wolf H. Expression of proteins encoded by Esptein-Barr virus transactivator genes depends on the differentiation of epithelial cells in oral hairy leukoplakia. Proc Natl Acad Sci U S A 1991; 88: 8332–8336
   PubMed Web of Science ®Google Scholar
• Sandvej K., Krenacs L., Hamilton Dutoit S. J., Rindum J. L., Pindborg J. J., Pallesen G. Epstein-Barr virus latent and replicative gene expression in oral hairy leukoplakia. Histopathology 1992; 20: 387–395
   PubMed Web of Science ®Google Scholar
• Young L. S., Lau R., Rowe M., Niedobitek G., Packham G., Shanahan F., Rowe D. T., Greenspan D., Rickinson A. B., Farell P. J. Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol 1991; 65: 2868–2874
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos I., Hummel M., Kreschel C., Stein H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 1995; 85: 744–750
   PubMed Web of Science ®Google Scholar
• Tao Q., Srivastava G., Chan A. C., Chung L. P., Loke S. L., Ho F. C. Evidence for lytic infection by Epstein-Barr virus in mucosal lymphocytes instead of nasopharyngeal epithelial cells in normal individuals. J Med Virol 1995; 45: 71–77
   PubMed Web of Science ®Google Scholar
• Tierney R. J., Steven N., Young L. S., Rickinson A. B. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994; 68: 7374–7385
   PubMed Web of Science ®Google Scholar
• Miyashita E. M., Yang B., Lam K. M., Crawford D. H., Thorley Lawson D. A. A novel form of Epstein-Barr virus latency in normal B-cells in vivo. Cell 1995; 80: 593–601
   PubMed Web of Science ®Google Scholar
• Decker L. L., Klamen L. D., Thorley-lawson D. A. Detection of the Latent Form of Epstein-Barr Virus DNA in the Peripheral Blood of Healthy Individuals. J Virol 1996; 70: 3286–3289
   PubMed Web of Science ®Google Scholar
• Prang N. S., Hornef M. W., JÄGer M., Wagner W. J., Wolf H., Schwarzmann F. Lytic replication of Epstein-Barr virus in the peripheral blood: Analysis of viral gene expression in B-lymphocytes during infectious mononucleosis and in the normal carrier state. Blood 1997; 89: 1665–1677
   PubMed Web of Science ®Google Scholar
• Yao Q. Y., Rickinson A. B., Epstein M. A. A reexamination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 1985; 35: 35–42
   PubMed Web of Science ®Google Scholar
• Yao Q. Y., Rickinson A. B., Epstein M. A. Oropharyngeal shedding of infectious Epstein-Barr virus in healthy virus-immune donors. A prospective study. Chin Med J Engl. 1985; 98: 191–196
   PubMed Web of Science ®Google Scholar
• Jäger M., Prang N., Mitterer M., Larcher C., Huemer H. P., Reischl U., Wolf H., Schwarzmann F. Pathogenesis of chronic Epstein-Barr virus infection: detection of a virus strain with a high rate of lytic replication. Br J Haematol 1996; 95: 626–636
   PubMed Web of Science ®Google Scholar
• Gratama J. W., Oosterveer M. A., Zwaan F. E., Lepoutre J., Klein G., Emberg I. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci USA 1988; 85: 8693–8696
   PubMed Web of Science ®Google Scholar
• Nemerow G. R., Mullen J. J., Dickson P. W., Cooper N. R. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection. J Virol 1993; 64: 1348–1352
   Google Scholar
• Fingeroth J. D., Weis J. J., Tedder T. F., Strominger J. L., Biro P. A., Fearon D. T. Epstein-Barr virus receptor of human B-lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 1984; 81: 4510–4514
   PubMed Web of Science ®Google Scholar
• Fischer E., Delibrias C., Kazatchkine M. D. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T-lymphocytes. J Immunol 1991; 146: 865–869
   PubMed Web of Science ®Google Scholar
• Bayliss G., Wolf H. An Epstein-Barr virus early protein induced cell fusion. Proc Natl Acad Sci USA 1981; 78: 7162–7165
   PubMed Web of Science ®Google Scholar
• Bayliss G. J., Wolf H. Epstein-Barr virus-induced cell fusion. Nature 1980; 287: 164–165
   PubMed Web of Science ®Google Scholar
• Sixbey J. W., Yao Q. Y. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science 1992; 255: 1578–1580
   PubMed Web of Science ®Google Scholar
• Sixbey J. W., Lemon S. M., Pagano J. S. A second site for Epstein-Barr virus shedding: The uterine cervix. The Lancet 1986; 2: 1122–1124
   PubMed Web of Science ®Google Scholar
• Kobayashi R., Takeuchi H., Sasaki M., Hasegawa M., Hirai K. Detection of Epstein-Barr virus infection in the epithelial cells of lymphocytes and non-neoplastic tonsils by in situ hybridisation and RT-PCR. Epstein-Barr virus & associated diseases, CSH. 1994; 89, 7–11 September, 1994
   Google Scholar
• Wolf H., Haus M., Wilmcs E. Persistence of Epstein-Barr virus in the parotid gland. J Virol 1984; 51: 795–798
   PubMed Web of Science ®Google Scholar
• Sam C. K., Brooks L. A., Niedobitek G., Young L. S., Prasad U., Rickinson A. B. Analysis of Epstein-Barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma. Int J Cancer 1993; 53: 957–962
   PubMed Web of Science ®Google Scholar
• Bogedain C., Wolf H., Modrow S., Stuber G., Jilg W. Specific cytotoxic T-lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J Virol 1995; 69: 4872–4879
   PubMed Web of Science ®Google Scholar
• Chen H. L., Lung M. L., Chan K. H., Griffin B. E., Ng M. H. Tissue distribution of Epstein-Barr virus genotypes. J Virol 1996; 70: 7301–7305
   PubMed Web of Science ®Google Scholar
• Okano M., Matsumoto S., Osato T., Sakiyama Y., Thiele G. M., Purtilo D. T. Severe chronic active Epstein-Barr virus infection syndrome. Clin Microbiol Rev 1991; 4: 129–135
   PubMed Web of Science ®Google Scholar
• Jones J. F., Straus S. E. Chronic Epstein-Barr virus infection. Annu Rev Med 1987; 195–209
   PubMed Web of Science ®Google Scholar
• Okano M., Thiele G. M., Davis J. R., Grierson H. L., Purtilo D. T. Epstein-Barr virus and human diseases: recent advances in diagnosis. Clin Microbiol Rev 1988; 1: 300–312
   PubMedGoogle Scholar
• Mitterer M., Pescosta N., Fend F., Larcher C., Prang N., Schwarzmann F., Coser P., Huemer H. P. Chronic active Epstein-Barr virus disease in a case of persistent polyclonal B-cell lymphocytosis. Br J Haematol 1995; 90: 526–531
   PubMed Web of Science ®Google Scholar
• Larcher C., Fend F., Mitterer M., Prang N., Schwarzmann F., Huemer H. P. Role of Epstein-Barr virus and soluble CD21 in persistent polyclonal B-cell lymphocytosis. Br J Haematol 1995; 90: 532–540
   PubMed Web of Science ®Google Scholar
• Alfieri C., Joncas J. H. Biomolecular analysis of a defective nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection. J Virol 1987; 61: 3306–3309
   PubMed Web of Science ®Google Scholar
• Alfieri C., Ghibu F., Joncas J. H. Lytic, non-transforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection. Can Med Assoc J 1984; 131: 1249–1252
   PubMed Web of Science ®Google Scholar
• Borysiewicz L. K., Haworth S. J., Cohen J., Mundin J., Rickinson A., Sissons J. G. Epstein-Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis. Exp Cell Res. 1986; 58: 111–121
   Google Scholar
• Fujieda M., Wakiguchi H., Hisakawa H., Kubota H., Kurashige T. Defective activity of Epstein-Barr virus (EBV) specific cytotoxic T-lymphocytes in children with chronic active EBV infection and in their parents. Acta Paediatr Jpn 1993; 35: 394–399
   PubMedGoogle Scholar
• Joncas J., Monczak Y., Ghibu F., Alfieri C., Bonin A., Ahronheim G., Rivard G. Brief report: killer cell defect and persistent immunological abnormalities in two patients with chronic active Epstein-Barr virus infection. J Med Virol 1989; 28: 110–117
   PubMed Web of Science ®Google Scholar
• Kibler R., Lucas D. O., Hicks M. J., Poulos B. T., Jones J. F. Immune function in chronic active Epstein-Barr virus infection. J Clin Immunol 1985; 5: 46–54
   PubMed Web of Science ®Google Scholar
• Kuis W., Roord J. J., Zegers B. J., Rickinson A. B., Kapsenberg J. G., ThÉ H., Stoop J. W. Heterogeneity of immune defects in three children with a chronic active Epstein-Barr virus infection. J Clin Immunol 1985; 5: 377–385
   PubMed Web of Science ®Google Scholar
• Tosato G., Straus S., Henle W., Pike S. E., Blaese R. M. Characteristic T-cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis). J Immunol 1985; 134: 3082–3088
   PubMed Web of Science ®Google Scholar
• Kenney S., Zalani S. Regulation of BZLF1 function by viral and host cell factors. Epstein-Barr Virus Report 1995; 2: 23–28
   Google Scholar
• Prang N., Wolf H., Schwarzmann F. Epstein-Barr virus lytic replication is controlled by a posttranscriptional mechanism of BZLF1. J Virol 1995; 69: 2644–2648
   PubMed Web of Science ®Google Scholar